A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants

International Journal of Infectious Diseases

Volumn 11, Issue 2, 2007, Pages 129-136

  Lin, Tzou Yien ^a   Wang, Ying Hsiang ^a   Chang, Luan Yin ^a   Huang, Yhu Chering ^a   Kao, Hsiu Tsun ^a   Lin, Pen Yi ^a   Lu, Hsiao Kuo ^a   Chavand, Pascale ^b   Ortiz, Esteban ^b  

^a CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

^b SANOFI PASTEUR   (France)

Author keywords

Acellular pertussis; Fully liquid combination vaccine; Haemophilus influenzae type b; Pentavalent vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; PEDIACEL; QUADRACEL; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ANOREXIA; ANTIBODY TITER; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIPHTHERIA; DROWSINESS; DRUG FORMULATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFANT; INFANT DISEASE; INJECTION SITE EROSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; POLIOMYELITIS; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SIDE EFFECT; TAIWAN; TETANUS; TREATMENT OUTCOME; VACCINATION; VIRUS INFECTION; VOMITING;

DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; INFANT; MALE; POLIOVIRUS VACCINE, INACTIVATED; TAIWAN; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 33847201507     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2005.10.014     Document Type: Article

References (15)

1. Edwards K.M., and Decker M.D. Pertussis vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 4th ed. (2004), Saunders, Philadelphia, Pa 471-528
2. Edwards K., Meade B., Decker M., Reed G.F., Rennels M.B., Steinhoff M.C., et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 96 (1995) 548-557
3. Decker M.D., Edwards K.M., Steinhoff M.C., Rennels M.B., Pichichero M.E., Englund J.A., et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 96 (1995) 557-566
4. Gustafsson L., Hallander H., Olin P., Reizenstein E., and Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334 (1996) 349-355
5. Olin P., Rasmussen F., Gustafsson L., Hallander H.O., and Heijbel H. Randomised controlled trial of two-component, three component, and five component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 350 (1997) 1569-1577
6. Mills E., Gold R., Thipphawong J., Barreto L., Guasparini R., Meekison W., et al. Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus B conjugate vaccine administered to infants at two, four and six months of age. Vaccine 16 (1998) 576-585
7. Farr R.S. A quantitative immunochemical measure of the primary interaction between I125 BSA and antibody. J Infect Dis 103 (1958) 239-269
8. Eskola J., Ölander R.M., Hovi T., Litmanen L., Peltola S., and Kayhty H. Randomized trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 348 (1996) 1688-1692
9. Eskola J., Ward J., Dagan R., Goldblatt D., Zepp F., and Siegrist C.A. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 354 (1999) 2063-2068
10. Pichichero M.E., Latiolais T., Bernstein D.I., Hosbach P., Christian E., Vidor E., et al. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four- and six-month infants. Pediatr Infect Dis J 16 (1997) 863-870
11. Käyhty H., Peltola H., Karanko V., and Mäkelä P.H. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 147 (1983) 1100
12. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 149 (1984) 1034-1035
13. Lee C.Y., Thipphawong J., Huang L.M., Lee P.I., Chiu H.H., Lin W., et al. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants. Pediatrics 103 (1999) 25-30
14. Scheifele D., Halperin S., Law B., and King A. Invasive Haemophilus influenzae type b infections in vaccinated and unvaccinated children in Canada. CMAJ 172 (2005) 53-56
15. Le Saux N., Barrowman N.J., Moore D.L., Whiting S., Scheifele D., and Halperin S. Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT. Pediatrics 112 (2003) 348-353